Teraura Hiroyuki, Kotani Kazuhiko, Minami Takaomi, Takeshima Taro, Shimooki Osamu, Kajii Eiji
1 Division of Community and Family Medicine, Center for Community Medicine, Jichi Medical University, Tochigi, Japan.
2 Department of Medicine, Iwate Prefectural Senmaya Hospital, Iwate, Japan.
Ann Clin Biochem. 2017 Mar;54(2):209-213. doi: 10.1177/0004563216677583. Epub 2017 Jan 12.
Kawasaki disease is a febrile disease of childhood that is associated with increased inflammatory cytokines and immunoregulatory abnormalities. While the serum concentrations of soluble IL-2 receptor can change under such pathologies, the relevance of the soluble IL-2 receptor concentration in patients with Kawasaki disease has not been specified. We aimed to summarize the existing studies that reported the soluble IL-2 receptor concentrations in patients with Kawasaki disease. Original articles that were published up to July 2016 were collected using a PubMed/Medline-based search engine. A total of nine articles that reported the serum soluble IL-2 receptor concentrations in acute-phase Kawasaki disease were eligible. All of the articles described a high soluble IL-2 receptor concentration in patients with Kawasaki disease relative to the level of controls or the reference range. Two of five articles on patients with coronary artery aneurysms described a significantly higher soluble IL-2 receptor concentration in patients with coronary artery aneurysms than patients without. Two articles on patients with intravenous immunoglobulin therapy described a significant decrease of the soluble IL-2 receptor concentration after the therapy. Accordingly, the serum soluble IL-2 receptor can be a potent marker of disease activity and therapeutic effects in patients with Kawasaki disease; further studies are thus warranted for its use in the clinical setting.
川崎病是一种儿童发热性疾病，与炎症细胞因子增加和免疫调节异常有关。虽然可溶性白细胞介素-2受体的血清浓度在这种病理情况下会发生变化，但川崎病患者中可溶性白细胞介素-2受体浓度的相关性尚未明确。我们旨在总结现有报道川崎病患者可溶性白细胞介素-2受体浓度的研究。使用基于PubMed/Medline的搜索引擎收集截至2016年7月发表的原始文章。共有9篇报道急性期川崎病血清可溶性白细胞介素-2受体浓度的文章符合要求。所有文章均描述川崎病患者的可溶性白细胞介素-2受体浓度相对于对照组水平或参考范围较高。五篇关于冠状动脉瘤患者的文章中有两篇描述冠状动脉瘤患者的可溶性白细胞介素-2受体浓度显著高于无冠状动脉瘤患者。两篇关于静脉注射免疫球蛋白治疗患者的文章描述了治疗后可溶性白细胞介素-2受体浓度显著降低。因此，血清可溶性白细胞介素-2受体可能是川崎病患者疾病活动和治疗效果的有力标志物；因此有必要进一步研究其在临床环境中的应用。
